Format

Send to

Choose Destination
Endocr J. 2019 Mar 28;66(3):241-251. doi: 10.1507/endocrj.EJ18-0352. Epub 2019 Feb 8.

High circulating follistatin-like protein 1 as a biomarker of a metabolically unhealthy state.

Author information

1
Asan Institute for Life Sciences, Seoul 05505, Korea.
2
Department of Nuclear Medicine, Kyung Hee University School of Medicine, Seoul 02447, Korea.
3
Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Songpa, Seoul 05505, Korea.
4
Department of Endocrinology, Inha University School of Medicine, Incheon 22332, Korea.
5
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Medical Center, Seoul 02053, Korea.
6
Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul 03722, Korea.
7
Department of Internal Medicine, Sejong General Hospital, Bucheon 14754, Korea.
8
Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul 07345, Korea.
9
Division of Endocrinology and Metabolism, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
10
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul 06591, Korea.

Abstract

The inflammatory biomarkers that fully characterize the metabolically unhealthy (MU) state-which is a risk factor for cardiovascular disease (CVD)-remain unclear. Recent studies suggest follistatin-like protein 1 (FSTL1) could be used as a biomarker for inflammation and CVD, however there is little information on FSTL1 levels in the MU state. We aimed to evaluate the associations between FSTL1, the presence of MU state and subclinical coronary atherosclerosis. In a cross-sectional study, we evaluated FSTL1 levels and their relationship with the presence of MU state and coronary artery plaques in 230 Korean patients. Significant increase in FSTL1 levels was observed in subjects with MU state (p = 0.020), but not those with obesity state according to body mass index criteria (p = 0.790). After adjusting for confounders, the odd ratio (OR) for the MU state among patients in the highest FSTL1 tertile (T3) was higher in comparison with the lowest tertile (T1) (OR = 3.60, 95% confidence interval [95% CI] = 1.20-10.83). In a subgroup (n = 66), FSTL1 levels were also marginally higher in patients with plaques (p = 0.098). The OR for plaque presence in patients with T3 was significantly higher in comparison with T1 after adjusting for confounders (OR = 12.51, 95% CI = 1.15-135.73). Plasma FSTL1 may be a useful biomarker for the risk of MU state and CVD.

KEYWORDS:

Follistatin-like protein 1; Metabolic unhealth; Subclinical atherosclerosis

PMID:
30745500
DOI:
10.1507/endocrj.EJ18-0352
Free full text

Supplemental Content

Full text links

Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
Loading ...
Support Center